Treatment with immune checkpoint inhibitors (ICIs) directed against the PD‐1/PD‐L1 axis has revolutionized cancer treatment, especially achieving substantial success in the management of patients with advanced non‐small cell lung cancer (NSCLC).1 This evidence concerns the gene CD274 and non-small cell lung carcinoma.